Title: Unique genetic profile of sporadic colorectal cancer liver metastasis versus primary tumours as defined by high-density single nucleotide polymorphism (SNP) – arrays.

Authors: Luís MUÑOZ-BELLVIS¹, Celia FONTANILLO², María GONZÁLEZ-GONZÁLEZ³, Eva GARCIA⁴, Manuel IGLESIAS¹, Carmen ESTEBAN¹, María Laura GUTIERREZ³, María del Mar ABAD⁵, Oscar BENGŒCHEA⁵, Javier DE LAS RIVAS², Alberto ORFAO*¹ and José María SAYAGUÉS*¹

* Both authors contributed equally to this work and should be considered as senior last authors

Institutions:
¹Unidad de Cirugía Hepatobiliopancreática, Departamento de Cirugía, Hospital Universitario de Salamanca, Salamanca, Spain.

²Grupo de Investigación en Bioinformática y Genómica Funcional, Centro de Investigación del Cáncer (IBMCC-CSIC/USAL), Universidad de Salamanca, Salamanca, Spain.

³Servicio General de Citometría, Departamento de Medicina and Centro de Investigación del Cáncer (IBMCC-CSIC/USAL), Universidad de Salamanca, Salamanca, Spain.

⁴Unidad de Genómica y Proteómica, Centro de Investigación del Cáncer (IBMCC-CSIC/USAL), Universidad de Salamanca, Salamanca, Spain.

⁵Departamento de Patología, Hospital Universitario de Salamanca, Salamanca, Spain.

Running head: Genetic profiling of liver metastases from colorectal carcinomas.

Key Words: liver metastases; colorectal cancer; copy number change; FISH; SNP-array.

Number of text pages: 28  Figures: 2  Tables: 3  Supplemental Files: 2

Reprint requests to:
Prof. Alberto Orfao, MD, PhD
Centro de Investigación del Cancer
Paseo de la Universidad de Coimbra S/N
37007 Salamanca, Spain
Tel: +34-923 29 48 11 Fax: +34-923 29 4624
E-mail: orfao@usal.es
**Financial Disclosure:** This work has been partially supported by grants from the Consejería de Sanidad, Junta de Castilla y León, Valladolid, Spain (SAN191/SA09/06, SAN673/SA39/08 and SAN/103/2011), Fundación Memoria de Don Samuel Solórzano Barruso, Salamanca, Spain, Caja de Burgos (Obra Social), Burgos, Spain, Grupo Excelencia de Castilla y León (GR37) and the RTICC from the Instituto de Salud Carlos III (ISCIII), Ministerio de Sanidad y Consumo, Madrid, Spain (RD06/0020/0035-FEDER). JM Sayagués and M González are supported by grants (CP05/00321 and FI08/00721, respectively) from the ISCIII, Ministerio de Ciencia e Innovación, Madrid, Spain.

**Conflict of interest statement**

None to declare.
ABSTRACT

Most genetic studies in colorectal carcinomas have focused on those abnormalities that are acquired by primary tumours, particularly in the transition from adenoma to carcinoma, while few studies have compared the genetic abnormalities of primary versus paired metastatic samples. In this study we used high-density 500K single-nucleotide polymorphism arrays to map the overall genetic changes present in liver metastases (n=20) from untreated colorectal carcinoma patients studied at diagnosis versus their paired primary tumours (n=20). MLH1, MSH2 and MSH6 gene expression was measured in parallel by immunohistochemistry. Overall, metastatic tumours systematically contained those genetic abnormalities observed in the primary tumour sample from the same subject. However, liver metastases from many cases (up to eight out of twenty) showed acquisition of genetic aberrations that were not found in their paired primary tumors. These new metastatic aberrations mainly consisted of 1) an increased frequency of genetic lesions of chromosomes that have been associated with metastatic colorectal carcinoma (1p, 7p, 8q, 13q, 17p, 18q, 20q) and, more interestingly, 2) acquisition of new chromosomal abnormalities (e.g. losses of chromosomes 4 and 10q and gains of chromosomes 5p and 6p). These genetic changes acquired by metastatic tumours may be associated with either the metastatic process and/or adaption of metastatic cells to the liver microenvironment. Further studies in larger series of patients are necessary to dissect the specific role of each of the altered genes and chromosomal regions in the metastatic spread of colorectal tumours.
INTRODUCTION

Occurrence of distant metastasis in sporadic colorectal cancer (e.g.: liver metastasis) confers a poor prognosis. In fact, metastatic disease is the main cause of death in colorectal carcinoma patients, and the liver is the most common site for metastatic spread of colorectal carcinoma.\textsuperscript{1,2} Current knowledge about the genetic pathways of clonal evolution in colorectal carcinoma, suggest that development of colorectal cancer could be triggered by the clonal expansion of cells that carry mutations which most frequently involve the \textit{APC}, \textit{RAS}, \textit{TP53} and/or \textit{DCC} genes and lead to a growth and/or survival advantage of tumour cells.\textsuperscript{3} As metastatic cells derive from primary tumour cells, specific genomic alterations driving these ultimate steps of the metastatic cascade are expected to be acquired over the genomic profile of neoplastic cells from the primary tumour.\textsuperscript{4} The genomic abnormalities which are potentially characteristic of such advanced stages of the disease are complex and so far, poorly described and partially understood. This relates to the fact that most genetic studies in colorectal cancer have focused on those abnormalities that are acquired in primary tumours particularly in the transition from adenoma to carcinoma, and few studies have compared these abnormalities with those observed in paired metastatic samples.\textsuperscript{5-7} Despite this, multiple recurrent chromosomal abnormalities which are found in primary tumours have been associated with metastatic colorectal carcinoma. Among others, these mainly include numerical changes such as gains of chromosomes 8q, 13q and 20q and losses of the 1p, 8p, 17p and 18q chromosomal regions.\textsuperscript{8-10} However, the molecular mechanisms underlying the association of such genetic profiles with metastatic colorectal carcinoma remain largely unknown.

Previous studies using conventional karyotyping,\textsuperscript{5} comparative genomic hybridization (CGH),\textsuperscript{5,7,11} fluorescence \textit{in situ} hybridization (FISH)\textsuperscript{9,11} or microsatellite
markers to detect regions of loss of heterozygosity (LOH), have largely failed in identifying recurrent chromosomal abnormalities acquired in metastatic vs. primary colorectal tumours. This could be explained at least in part, because of the relatively limited resolution of these techniques. More recently, the availability of high-density single nucleotide polymorphism (SNP)-arrays has facilitated the identification of small regions of chromosomal gains and losses because of its higher resolution (down to 2.5 kb) and provides new opportunities in the identification of novel cancer genes involved in the metastatic process of colorectal cancer. However, previous reports in which high-density SNP-arrays have been used to investigate the genetic profiles of colorectal carcinoma have specifically focused on primary tumour samples and to the best of our knowledge, no study has been reported so far in which high-density SNP-arrays are employed to investigate the potential genetic differences between paired primary and metastatic tumours from colorectal carcinoma patients.

In the present study, we applied high-density (500K) SNP mapping arrays - mean distance between the interrogated SNPs of 5.8 kb (median intermarker distance of 2.5 kb)- to map the overall genetic changes present in liver metastases from 20 untreated colorectal carcinoma patients studied at diagnosis versus their paired primary tumours (n=40 samples). Our goal was to search for recurrent genetic differences between paired primary vs metastatic tumour samples that might contain candidate genes highly characteristic of metastatic liver disease.
MATERIALS AND METHODS

Patients and samples. Tissue specimens from 20 sporadic colorectal adenocarcinomas and 20 paired liver metastases (n=40 samples) were obtained from 20 patients (13 males and 7 females; median age of 70 years, ranging from 49 to 80 years) after informed consent had been given by each subject. It should be noted that only patients with metastatic lesions able to be resected were included in this cohort, which therefore is not representative of the whole colorectal cancer patient population. All patients underwent surgical resection of both tumour tissues at the Department of Surgery of the University Hospital of Salamanca (Salamanca, Spain). All tumours were diagnosed and classified according to the WHO criteria\textsuperscript{15} and they were all studied prior to any treatment was given. According to tumour grade, 11 cases were classified as well-differentiated tumours, 8 as moderately- and one as poorly-differentiated carcinomas. In all cases, histopathological grade was confirmed in a second independent evaluation by an experienced pathologist. Median follow-up at the moment of closing the study was of 37 months (range: 36-96 months). The study was approved by the local ethics committee of the University Hospital of Salamanca (Salamanca, Spain).

Seven primary tumours were localized in the rectum and the other 13 either in the right (caecum, ascending or transverse) or the left (descending and sigmoid) colon. The mean size of primary tumours was of 5.3 ± 1.9 cm with the following distribution according to their TNM stage at diagnosis:\textsuperscript{16} T3N0M0, 2 cases; T3N1M1, 4; T3N1M0, 4; T3N2M1, 4; T4N0M1, 1; T4N0M0, 3; T4N1M1, 1 and; T4N2M1, 1 case. Liver metastases were identified either at the time of colorectal surgery (n= 11) or during the first year after initial diagnosis (n=9); to date patients have not shown any other metastasis. The mean size of liver metastases was of 4.3 ± 2.2 cm.
After histopathological diagnosis was established, part of the primary tumour and its paired liver metastasis (both corresponding to a macroscopically tumoral region) were used to prepare single-cell suspensions. Once prepared, single cell suspensions were resuspended in methanol/acetic (3/1; vol/vol) and stored at -20°C for further interphase FISH analyses, as recently described. The remaining tissue was either fixed in formalin and embedded in paraffin, or frozen in liquid nitrogen and stored at room temperature or at -80 °C, respectively. All tissues were evaluated after haematoxylin-eosin staining to confirm the presence of tumour cells and to evaluate their quantity in each individual sample. For SNP-array studies, tumour DNA was extracted from representative areas of freshly frozen tumour tissues (primary tumours and liver metastases), which contained ≥65% epithelial tumour cells localized mirror cut to those used for iFISH analyses. In turn, normal DNA was extracted from peripheral blood leukocytes from the same patient. For the three types of samples (primary tumors, paired liver metastases and peripheral blood leukocytes), DNA was extracted using the QIAamp DNA mini kit (Qiagen, Hilden, Germany) following the instructions of the manufacturer.

**SNP-array studies.** Each DNA sample derived from primary tumours and liver metastases and normal peripheral blood leukocytes was hybridized to two different 250K Affymetrix SNP Mapping arrays (NspI and StyI SNP arrays, Affymetrix, Santa Clara, CA); for this purpose 250 ng of DNA per array was used, according to the instructions of the manufacturer. Fluorescence signals were detected using the Affymetrix GeneChip Scanner 3000 (Affymetrix) and average genotyping call rates of 94.4%, 91.5% and 97.3% were obtained for primary tumors, liver metastases and normal peripheral blood DNA samples, respectively.
In order to identify copy number changes throughout the whole tumour genome, the *aroma.affymetrix* algorithm was used, following the CRMA v2 method described elsewhere\(^\text{18}\) (R-software package, [http://www.aroma-project.org](http://www.aroma-project.org)) and the following sequential steps: i) calibration for crosstalks between pairs of allele probes; ii) normalization for probe nucleotide-sequence effects, and; iii) normalization for PCR fragment-length and probe localization effects. Then, data from the 250K *StyI* and 250K *NspI* arrays was integrated into a single database and raw copy number values were calculated as transformed log2 values of the primary tumour/normal peripheral blood, liver metastasis/normal peripheral blood, liver metastases/primary tumour ratios calculated for each individual patient.

In order to identify DNA regions with similar copy number values we used Circular Binary Segmentation as implemented in the DNAcopy Bioconductor package\(^\text{19}\) with the default parameters; a p-value ≤ 0.01 for ≥ 5 markers per DNA segment was used to define points with changes. We used the smoothed value by assigning the median segment value to each probe. For the identification of altered (gained or lost) DNA regions a threshold was established based on the changes observed in the fluorescence intensity of sequential DNA segments for primary tumour versus peripheral blood, liver metastasis versus peripheral blood and for liver metastases versus primary tumor samples, for each of the 20 patients studied. Log2 ratio values > 0.09 and < -0.09 were used as cut-off thresholds to define the presence of increased and decreased copy number values, respectively. High-level gains (DNA amplification) were defined as regions with a mean log2 copy number ratio ≥0.25. The specific frequencies of both copy number gains and losses per SNP were established and plotted along individual chromosomes for each tumour sample analyzed, for all individual cases studied. Based on the empirical frequency distribution of gains and losses among
the 20 primary and the 20 metastatic tumor samples respectively, we took the common altered regions grouping the contiguous SNPs with adjusted p-values < 0.01 (False Discovery Rate correction based on the Benjamini and Hochberg procedure). Minimal common regions were defined as the smallest subset of SNPs in the altered regions with the highest frequency of gains and losses. At least 5 contiguous SNPs were required to define a region. Genes in these regions were identified using Ensembl release 53 (http://www.ensembl.org). The pattern of copy number changes of the primary tumors here analyzed has been previously reported in detail in a recent study.21

**Interphase fluorescence in situ hybridization (FISH) studies.** In order to evaluate the reproducibility of the SNP-array results and to assess background noise impact of this technique, interphase FISH analyses of the same tumour samples was performed in parallel using 24 probes directed against an identical number of regions from 20 different human chromosomes, which are frequently altered in sporadic colorectal carcinomas. Overall, our results showed a high degree of correlation between both methods; this also holds true when such analysis was restricted to the most frequently altered regions, as previously described.21

**Immunohistochemistry.** One block of formalin fixed paraffin wax embedded adenocarcinoma tissue was selected in each case. In all cases, this block comprised an area of normal colonic mucosa adjacent to the tumour. Sections (4 µm) were affixed to Superfrost plus slides (CML, Nemours, France) and dried overnight at 37°C. Paraffin was removed and the tissue rehydrated using xylene and ethanol. Slides were subjected to microwave antigen retrieval in 10 mM citrate buffer (pH 6) at 85°C for 35 min and cooled in phosphate-buffered saline, pH 7.4 (Sigma). Endogenous peroxidase activity was blocked with 2% hydrogen peroxide in methanol and slides were washed with
phosphate-buffered saline prior to overnight incubation with the appropriate antibody at a dilution of 1:100. Commercially available monoclonal antibodies against the nuclear proteins MLH1 (Clone G168-15; BD Biosciences, San Jose, CA, USA), MSH2 (Clone FE11; Biocare Medical, CA, USA) and MSH6 (Clone BC/44; Biocare Medical) were applied, followed by staining with Strept ABC complex/HRP Duet kit (DAKO, Copenhagen, Denmark) in conjunction with diaminobenzidine 180 mg in 300 ml phosphate-buffered saline with 300 ml hydrogen peroxide. Sections were washed under running tap water and then lightly counterstained in Mayer’s haematoxylin. Loss of expression was recorded when nuclear staining was absent from all malignant cells but preserved in normal epithelial and stroma cells. Two observers assessed all cases independently.

**Statistical methods.** For all continuous variables, mean values and their standard deviation and range were calculated using the SPSS software package (SPSS 12.0 Inc, Chicago, IL USA); for dichotomic variables, frequencies were reported. In order to evaluate the statistical significance of differences observed between groups, the Mann-Whitney U and the $X^2$ tests were used for continuous and categorical variables, respectively (SPSS).
RESULTS

Frequency and chromosomal localization of copy number changes in liver metastasis from colorectal carcinoma. Overall, liver metastases from the 20 colorectal cancer patients analyzed, systematically contained those chromosomal abnormalities that were identified in their paired primary colorectal carcinomas; (please note that the later have been previously described in detail for a larger series of patients).21 Despite this, some aberrations were either newly acquired or more frequently found in liver metastases than in their paired primary tumours, which could reflect an increased genetic instability of neoplastic cells from metastatic vs. primary tumor samples (Figure 1).

In detail, all liver metastases showed copy number changes in at least one chromosomal region. The highest frequency of copy number losses detected corresponded to chromosomes 1p (n=16; 80%), 17p (n=18; 90%) and 18q (n=19; 95%); in turn, copy number gains more frequently involved chromosomes 7p (n= 18; 90%), 8q (n=15; 75%), 13q (n=14; 70%) and 20q (n=15; 75%) (see Supplemental Table S1). Interestingly, each of these regions has been previously found to contain genes which are altered/involved in colorectal cancer (e.g.: ANGPT2, UBR5, KLF10, EIF3H, NOV, DCT, ABCC4, SLC15A1, EFNB2, IRS2, ING1, MAP2K4, ID1, BCL2L1, MYLK2, CBFA2T2 and E2F1) and/or genes that are relevant to the metastatic process (e.g.: ANGPT2, RRM2B, KLF10, RAD21, NOV, POU4F1, SPRY2, DCT, CLDN10, EFNB2, IRS2, COL4A2, ING1, MYH8, MAP2K4, ID1, BCL2L1, TPX2, MYLK2 and E2F1) in addition to genes associated with other malignancies (i.e.: TRPS1, BTF3L1, DNAJC3, STK24, TM9SF2, LIG4, ARHGEF7, SCO1, MYOCD, GALR1, HCK and SMC1B) (Table 1). From them, the ANGPT2, MAP2K4, E2F1, ID1 and BCL2L1 genes have been
reported to be involved in mechanisms that lead to increased cell proliferation and angiogenesis, and they have been found to be altered in both colorectal cancer and the metastatic events.

**Frequency and chromosomal localization of high-level copy number gains in liver metastases from colorectal carcinomas.** Chromosome 7 showed 17 regions which displayed high level genetic amplification (Table 2) with mean log2 ratio fluorescence intensities of 0.28 (range: 0.25 to 0.36). These 17 regions were distributed along the whole chromosome 7 at the 7p22, 7p21, 7p15, 7p12, 7q22 and 7q36 chromosome bands and they were all found to be altered (amplified) in ≥ 14/20 cases studied (70%) (see Supplemental Table S2). These regions contain multiple genes which have been recurrently associated with the pathogenesis of colorectal cancer and the metastatic process: *FSCN1, TWIST1, ITGB8, DFNA5, HOXA7, GRB10, EGFR, AZGP1, MCM7, EPHB4* and *MUC3A* (Table 2). In turn, for chromosome 8 only two regions of high level genetic amplification (mean fluorescence intensities of 0.42 and 0.37, respectively) were detected; both regions were localized at the 8q24 chromosome band, and they involved the *MTSS1* and *ASAP1* genes (Table 2). Additionally, chromosomes 13 and 20 also displayed three regions (two in chromosome 13 and one in chromosome 20) with high level genetic amplification (mean fluorescence intensities of 0.45 and 0.43, respectively) containing genes potentially involved in the pathogenesis of colorectal cancer and the metastatic process, the *KLF5, IRS2* and *MMP9* genes coded in the 13q22.1, 13q34, and 20q13.12 chromosomal regions (Table 2).

**Acquired chromosomal abnormalities in liver metastases.** In individual patients, primary tumors and their paired liver metastases frequently revealed the same chromosomal changes at both sites (Figure 1). However, liver metastases from eight out of twenty cases showed acquisition of new genetic abnormalities that were not found in
their paired primary tumors. These new metastatic aberrations included copy number gains at chromosomes 2p, 5p, 6p, 7q and 11p together with copy number losses of chromosomes 4, 5q and 10q (Table 3). The specific abnormalities which were recurrently detected in 8/20 colorectal carcinomas metastasis for those chromosomal regions that showed a normal diploid profile in their corresponding (paired) primary tumors, are shown in figure 2. As illustrated, these metastatic abnormalities involved chromosomal regions which harbor i) tumor suppressor genes that play a key role in the metastatic process (e.g.: the ANXA5, CCNA2, IL2 and IL21 genes at chromosome 4q27; the PLK4, IL15, GAB1, HHIP and SMAD1 genes coded at the 4q28.1 chromosome regions and the PTEN gene coded at the 10q23.33 chromosomal region) and; ii) oncogenes (e.g.: the PTGER4 and PRKAA1 genes coded at chromosome 5p13.1 and both the RIPK1 and NQO2 genes coded at chromosome 6p25.2); copy number gains of the former two oncogenes have been associated with advanced colorectal carcinoma. Many other genetic aberrations were present in liver metastases from colorectal carcinoma analyzed but at lower frequencies (Figure 1).

**Correlation between the chromosomal changes detected by interphase FISH and SNP-arrays studies.** Overall, the chromosomal abnormalities identified by interphase FISH in liver metastases showed profiles similar to those found by SNP-array studies, also when such analysis was restricted to the most frequently altered regions. Thus, gains/amplification at 7q were detected in 60% of the cases by interphase FISH versus 70% by SNP-arrays studies ($r^2=0.67; p<0.001$); similarly, gains/amplification of chromosomes 8q (found in 70% of cases by interphase FISH versus 75% by SNP-arrays studies; $r^2=0.79; p<0.001$), 13q (80% versus 70%; $r^2=0.78; p<0.001$) and 20q (80% versus 75%; $r^2=0.80; p<0.001$) as well as deletions of chromosomes 8p (65% versus 70%; $r^2=0.81; p<0.001$), 17p (75% versus 90%; $r^2=0.64$;
p=0.02) and 18q (75% versus 95%; $r^2=0.63$; p=0.03) were detected at similar frequencies with both methods.

**Microsatellite status.** All primary tumours examined (n=20) showed a normal expression of the MLH1, MSH2 and MSH6 mismatch repair proteins in the nucleus and adjacent non-neoplastic tissue elements.
DISCUSSION

This study focused on the genetic characterization of liver metastases that occur in the context of primary colorectal carcinoma. To the best of our knowledge, this is the first study that compares the genetic abnormalities found in liver metastases vs. paired primary colorectal tumours, in which high-resolution 500K SNP arrays have been systematically used. Overall, primary tumours and their paired metastases from individual patients, frequently revealed many common chromosomal changes at both sites; these findings support the existence of a close genetic relationship between primary colorectal tumours and their paired liver metastases, as previously suggested.\textsuperscript{17}

Genetic changes observed in common in both groups of samples included gains of chromosomes 7, 8q, 13q and 20 and losses of the 1p, 4, 8p, 17p, 18 and 22q chromosomes with normal expression of the MLH1, MSH2 and MSH6 mismatch repair proteins. In line with other studies, all our metastatic tumours showed a higher frequency of these chromosomal abnormalities than primary colorectal tumors\textsuperscript{7,22} and some of these abnormalities, together with deletions on chromosome 15q, have been associated with disease progression.\textsuperscript{23} Previous studies in which the genetic abnormalities of colorectal carcinoma have been investigated by conventional cytogenetics,\textsuperscript{24} FISH,\textsuperscript{17} CGH,\textsuperscript{25} array CGH\textsuperscript{26} and low-resolution 50k SNP-arrays\textsuperscript{23} have also found that most of these genetic abnormalities are recurrently identified in primary tumours from metastatic colorectal carcinoma. Based on the high frequency of these chromosomal abnormalities in both primary and metastatic samples, it could be hypothesized that they reflect a metastatic genetic profile of colorectal carcinoma that could be of great clinical utility for the identification of colorectal carcinoma patients at higher risk of developing liver metastases, already at diagnosis.
Interestingly, high-level genetic amplification was found at specific regions of chromosomes 7, 8, 13 and 20; overall 43 genes commonly involved/altered in colorectal cancer and/or associated with the metastatic process, are coded in these regions. Of note, 17 of these 43 genes have been associated with progression of hepatocellular carcinomas.\textsuperscript{27-29} Altogether, these findings could suggest that these genetic abnormalities that are acquired by metastatic colorectal carcinoma cells in the liver could be associated with homing and/or adaptation to the liver microenvironment. Among these genes, overexpression of \textit{TWIST1} has been demonstrated to induce angiogenesis at the same time it has been associated with both the development of metastasis in hepatocellular carcinomas \textsuperscript{30} and an unfavorable outcome in colorectal carcinoma patients;\textsuperscript{31} in turn, increased expression of \textit{IRS2} -commonly found in human hepatocellular carcinoma specimens and hepatoma cell lines \textsuperscript{32} has been associated with colon tumorigenesis where it contributes to tumor progression and an aggressive clinical behavior.\textsuperscript{33} In line with this hypothesis, preliminary studies on genomic differences detected in primary colorectal carcinomas versus paired brain metastases have described a genetic profile consisting of gains of 8q, 12p, 12q, 20p, and loss of 5q in brain metastasis\textsuperscript{34} which is clearly different from that observed in our liver metastases. The different genetic signature associated to liver vs. brain metastases could mirror the unique adaptation process of metastatic tumour cells to each specific microenvironment. Despite these findings, those three chromosomal regions which showed the highest levels of amplification were 13q31.3, 13q34 and 20q13.33, where four known cancer genes (\textit{MIRHG1, COL4A1, COL4A2} and \textit{CDH4}) are coded. To the best of our knowledge, no specific association between amplification of these genes and colorectal carcinoma has been reported so far; conversely, deregulation of these genes
has been associated with neuroblastoma,\textsuperscript{35} esophageal squamous cell carcinoma\textsuperscript{36} and glioblastoma multiforme.\textsuperscript{37}

In the present study, we also show the existence of recurrent genetic changes between paired primary and metastatic colorectal tumour cells. Such changes mainly consist of 1) an increased frequency of genetic lesions of chromosomes that have been associated with metastatic colorectal carcinoma (1p, 7p, 8q, 13q, 17p, 18q, 20q) and, more interestingly, 2) acquisition of new chromosomal abnormalities (e.g. losses of chromosomes 4 and 10q and gains of chromosomes 5p and 6p). Interestingly, the former abnormalities involved chromosomal regions that encode for up to 11 genes which have been previously found to be involved in the metastatic process of colorectal carcinoma. As an example, the $\text{ANGPT2}$ gene (localized in chromosome 8 at 8p23.1) is known to be involved in angiogenic processes and has been previously associated with an invasive/malignant potential;\textsuperscript{38} in turn, the $\text{E2F1}$ gene (20q11.21) has been shown to play a crucial role in the control of cell cycle through down-regulation of tumor suppressor proteins.\textsuperscript{39} Similarly, the $\text{ID1}$ and $\text{BCL2L1}$ genes (both coded in the same chromosomal region at 20q11.21) are also known to play a role in cell growth, senescence and differentiation, and the carcinogenesis of human colorectal carcinoma,\textsuperscript{40} while overexpression of the Id-1 protein has been associated with tumour progression in colorectal carcinoma.\textsuperscript{41} In turn, Paredes \textit{et al} have recently described that losses of chromosome 17p in metastatic colorectal cancer samples cover larger regions than in primary tumours, suggesting that additional unknown suppressor genes could be present at 17p, in the newly deleted sequences.\textsuperscript{11} In line with these findings, we have recurrently identified loss of the $\text{MAP2K4}$ gene (mitogen-activated protein kinase kinase-4) at 17p12 in the great majority of the metastatic samples analyzed. The $\text{MAP2K4}$ gene is a
member of the stress-activated protein kinase signaling cascade involved in the regulation of multiple cellular processes, which among other associations, has been recently suggested to play a functional role as a metastasis-suppressor gene in several malignant tumours, e.g. human prostatic cancer, ovarian cancer as well as breast and pancreatic tumors. Similarly, a potential role for 18q LOH in the development of colorectal cancer with associated liver metastases has been suggested, as well as its potential independent prognostic value, which may depend on the microsatellite instability status. In this regard, chromosomal instability has been associated in colorectal cancer with a worse prognosis and different groups of tumors have been defined based on chromosomal instability status. Herein, we identified loss of the 18q22-q23 chromosomal region in the great majority (95%) of the metastatic samples analyzed; interestingly, no clear association could be found between 18q LOH and the microsatellite instability status due to normal expression of the MLH1, MSH2 and MSH6 mismatch repair genes and potentially also the relatively limited number of cases studied. Similarly, the sample size and the presence of multiple structural and/or numerical chromosome changes in all liver metastases analyzed precludes the study of chromosomal instability subtypes.

Many patients also showed acquisition of new genetic aberrations which were not detected in their paired primary tumours. These included gains of chromosomes 2, 5p, 6p, 7q and 11p and losses of chromosomes 4 and 10q. These results suggest that these chromosomal regions may also play a relevant role in the metastatic process as supported by the fact that some of them -e.g.: del(4p15.33), del(4q22.3), del(4q27), del(4q28.1), del(4q31), del(4q35.1) and del(10q23)- are known to contain multiple tumor-suppressor genes (e.g. PLK4 at 4q28.1, SFRP2 at 4q31.3, IRF2 at 4q35.1 and
PTEN at 10q23.2\textsuperscript{48-51} and genes that are involved in the metastatic process.\textsuperscript{52-54} In line with these findings, previous studies in which primary colorectal carcinomas were compared with liver metastases also reported a greater frequency of chromosome 4 losses in late vs. early stages of the disease.\textsuperscript{9,55} However, due to the limited sensitivity of the SNP-array technique for the detection of small clones that could already be present in primary tumors, further studies in which such abnormalities are investigated at the single cell level are required to confirm our findings.

In summary, here we show the existence of relevant genetic differences between paired primary and metastatic colorectal tumours which mainly consist of 1) an increased frequency of genetic lesions of chromosomes that have been associated with metastatic colorectal cancer (1p, 7p, 8q, 13q, 17p, 18q, 20q) and, more interestingly, 2) acquisition of new chromosomal abnormalities (e.g. losses of chromosomes 4 and 10q and gains of chromosomes 5p and 6p). These genetic changes acquired by metastatic tumours may be associated with either the metastatic process and/or adaption of metastatic cells to the liver microenvironment. Further studies in larger series of patients in which cases with non-resectable liver metastasis are also analyzed, are necessary to dissect the specific role of each of the altered genes and chromosomal regions in the metastatic spread of colorectal tumours. Additional gene expression profile studies are required to validate the proteins associated with copy number alterations in the metastasis versus the primary tumor.
References


16 Greene FL. Current TNM staging of colorectal cancer. Lancet Oncol 2007;8:572-573


20 Benjamini Y, Hochberg Y. On the adaptive control of the False Discovery Rate in multiple testing with independent statistics. JEBS 2000;25:60–83


48 Baselga J. The EGFR as a target for anticancer therapy--focus on cetuximab. Eur J Cancer 2001;4:S16-S22


**LEGENDS TO FIGURES**

**Figure 1**: Metastatic colorectal cancer genome for the 20 colorectal carcinoma patients genotyped on the Affymetrix 500k SNP array platform. A summary plot showing the frequency (panel A in the left) and fluorescence intensity log2 ratios (panel B in the left) of those copy number gains (plotted in red above zero values in the x-axis) and losses (plotted in green below zero values in the x-axis) identified in primary sporadic colorectal tumors (light colors) and their paired liver metastases (dark color) are displayed for the whole genome. The panels in the right show abnormalities identified in primary sporadic colorectal tumors (light colors) and their paired liver metastases (dark color) for individual chromosomes which showed new abnormalities in metastatic versus primary tumour samples (panels C to H), or displayed an increased frequency of abnormalities in metastatic samples which were already detected in primary tumours (panels I to Q). Arrows point to regions of interest.

**Figure 2**: Metastatic colorectal cancer genome for the 20 colorectal carcinoma patients genotyped on the Affymetrix 500k SNP array platform; copy number changes detected in liver metastases (n=8/20 cases; red color) versus their paired primary tumors (blue color) for the 4q27, 4q28.1, 4q34.1, 5p13.1, 6p25.2 and 10q23.33 chromosomal regions (Panel A). Genes contained in the newly altered chromosomal regions are listed in italics capital letters. Log2 ratios > 0.09 and < -0.09 (shown as coloured background) were used as cut-off thresholds to define the presence of increased and decreased copy number values, respectively. All copy number changes detected between liver metastases versus their paired primary tumours showed statistically significant differences (p<0.001). As an example, the 3p14, 12q12 and 19q13 chromosomal regions which did not show any differences between paired primary and metastatic lesions are also shown (Panel B).